Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-12 am EDT			5-day change	1st Jan Change
287.25 ^DKK	+1.66%		+1.20%	-11.68%

Jun. 12	European shares rally as Middle East peace hopes drag oil prices lower	RE
Jun. 12	Analyst recommendations: Adobe, CME Group, Nvidia, Flutter…

NOVO NORDISK : Jefferies reaffirms its Neutral rating

Published on 05/13/2026 at 02:47 am EDT

MarketScreener with dpa-AFX Analyser

NOVO NORDISK A/S

+1.66%

Jefferies confirms his opinion on the stock and remains Neutral. The target price is still set at DKK 270.

Latest news about Novo Nordisk A/S

Jun. 12	European shares rally as Middle East peace hopes drag oil prices lower	RE
Jun. 12	Analyst recommendations: Adobe, CME Group, Nvidia, Flutter…
Jun. 12	Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027	MT
Jun. 12	Wall Street Wants to Believe Again
Jun. 12	WINNERS & LOSERS: Virgin Wines cuts guidance; Cizzle rises on patent	AN
Jun. 12	MedPal AI highlights UK approval of Novo Nordisk weight-loss pill	AN
Jun. 12	After Euphoria, a Traffic Jam on the Multi-Billion Dollar Kilo-Highway
Jun. 12	European Midday Briefing : Oil Falls After Trump Calls Off Iran Strikes	DJ
Jun. 12	European stocks rally as oil falls on US-Iran deal prospects	RE
Jun. 12	FTSE 100 surges as Trump claims Iran deal imminent	AN
Jun. 12	European stocks rally as oil falls on hopes for US-Iran deal	RE
Jun. 12	UK economy contracts in April; Flutter to leave LSE	AN
Jun. 12	MedPal AI Says New Health Clinic Could Benefit from UK Approval of Oral Weight Loss Drug	MT
Jun. 12	Is There Life on Mars?
Jun. 12	UK Stocks-Factors to watch on June 12	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

67,900

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company